Navigation Links
New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO

patients with advanced refractory thyroid cancer.

-- Overall survival in patients with advanced pancreatic cancer treated with axitinib in combination with gemcitabine or gemcitabine alone.

-- Single-agent efficacy and safety of axitinib in advanced, refractory NSCLC.

Signal Transduction

-- A phase II trial evaluated the safety and efficacy of the investigational compound CP-751,871 in combination with paclitaxel and carboplatin as first-line treatment for NSCLC and standard therapy (paclitaxel and carboplatin alone).

Immuno-Oncology

-- Four different presentations evaluating CP-675,206 in metastatic melanoma and one presentation evaluating CP-675,206 in refractory CRC will be unveiled at ASCO.

-- Results from a multi-dose phase I/II clinical trial that evaluated safety, response, and survival in patients with advanced metastatic melanoma treated with CP-675,206 will be presented in an oral presentation. Two different dosing regimens were evaluated in the phase II arm, providing information on the selected dosing regimen in the phase III program.

Pfizer also announced the expansion of the clinical trial program evaluating the efficacy and safety of sunitinib malate in the treatment of breast cancer. Pfizer has initiated three additional phase III trials to further evaluate sunitinib malate in metastatic breast cancer. This robust research program now includes a total of four phase III and two phase II trials and will include more than 2,600 patients worldwide.

Phase III programs evaluating sunitinib malate in CRC, NSCLC and liver cancer will also be initiated. Professionals interested in learning more about sunitinib malate trials in various cancers can access www.suntrials.com - a clinical resource for healthcare providers.

"SUTENT has proven to be an important therapy in the treatment of advanced kidney cancer and imatinib-resistant gastrointestinal stromal tumor, for which it is currently appr
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
5. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
8. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
9. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
10. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
11. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
Post Your Comments:
(Date:8/21/2008)... Aug. 21 /-,Bayer HealthCar...Inc.,(Nasdaq: ONXX ) today announced the companie...enib as Adjuvant Treatment in the Prevention of,Re...ndomized, double-blind,placebo-controlled Phase 3...s as adjuvant treatment, which is treatment follow...
(Date:8/20/2008)...nobia Pharma, an emerging biotech,company focused ...disorders, today announced that the first patient ...een dosed. Enobia is investigating Enzyme,Replacem...of this rare and,often crippling genetic bone diso...nder two separate protocols, ENB-0040 will be eval...
(Date:8/19/2008)...-,Pharmaceutical company Ph...hat the Phase 3 clinical trial evaluating the long...iectasis has concluded with no serious,adverse eve...treatment., A total of 123 subjects started treat...ubjects completed the full 12 months of the trial....
(Date:8/19/2008)...be used to identify molecular,signature of motor n...ire-USNewswire/ -- ALS Therapy,Development Institu...n ALS,biomarker effort using blood samples collect...ships. These ongoing projects are part of the,Inst...expression of genes,and proteins, at the onset of,...
Breaking Medicine Technology:Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 2Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 3Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 4Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 5Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 2Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 312 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 212 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 3ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Researchers discover natural herbicide released by grass 1144 1Researchers discover natural herbicide released by grass 1144 2St Jude program reduces weight gain in young African American girls 5856 1St Jude program reduces weight gain in young African American girls 5856 2Skin Cancer Prevention Update 3A 5853 1Skin Cancer Prevention Update 3A 5853 2Skin Cancer Prevention Update 3A 5853 3Skin Cancer Prevention Update 3A 5853 4Skin Cancer Prevention Update 3A 5853 5Feeling Stressed 3F 5850 1Feeling Stressed 3F 5850 2Feeling Stressed 3F 5850 3Feeling Stressed 3F 5850 4
...ased Enzyme Levels in Two Most Common Mutations, C...us,Therapeutics, a biopharmaceutical company devel...logical chaperones for the,treatment of a range of...ill present the results of preclinical studies of,...cher disease at,the of Medical Genetics (ACMG) ann...
...clinical Studies Presented at the Targeted,Antican... Molecular,Targets for Cancer Meetings Support Pha...rch 20, 2007,/PRNewswire-FirstCall/ -- Sunesis Pha...n its development-stage compound, SNS-314, at,two ...ticancer,medicines. Findings from in vitro and in ...
Other Medicine Technology:Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 2Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 3
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...ing system for use by physicians predicts early ri...ransient ischemic attack, known as TIA and also ca...out 240,000 TIAs are diagnosed every year in the U...United Kingdom. A TIA is a serious condition cause...
...nase (ADH) is one of the major enzymes involved in...phic at two loci, ADH1B and ADH1C.// The three al...ed with protection from alcohol dependence, a new ...tionship between the ADH1B*3 allele and alcohol-re...
...global acquisitions last year, India's Ranbaxy Lab...the generic drugs business of German// pharmaceuti...llion. ‘We are in talks with private equity funds... executive Malvinder Singh said on the margins of ...
...ochrane Review concluded antidepressants bupropion...es //of giving up smoking and have few side-effect...RIs) such as fluoxetine (Prozac) are not effective...own to help people quit smoking, not everyone is h...
Other Medicine News:Health News:New Tool Improves Prediction of Stroke Risk 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 3
The QIAamp Viral RNA Mini Kit allows purification of viral nucleic acids from cell-free fluid samples. Examples of viral nucleic acids that can be isolated with this kit include, but are not limited
The PersonalLAB junior is an automated microplate analyzer capable of fully automating immunoenzymatic techniques using a microplate format, per the reagent manufacturer's instruction for use and spe
MAP D-Type can combine a number of assay steps for up to 180 microplates on a simple to use benchtop device. The D-Type base instrument is a multifunctional stand-alone device but also provides easy
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi
Medicine Products: